News

Manufacturing

Next Phase of Pharma Growth: Generics

Michael McTague | Equities.com |

Here Come the Generics!

Investors have been rattled by many pieces of bad news for months but the massive pharmaceutical industry brings some relief. For 2022, Pfizer (PFE) is looking at an additional $20 billion in revenue over last year, actually a repeat of its 2021 versus 2020 performance. Their assets are way up and feature $31 billion in cash. Johnson and Johnson (JNJ), which is looking at more than $95 billion in revenue this year, has about the same...


This ’Niche‘ IoT Sector Is Set to Boom

Justin Spittler | Equities.com |

By Justin Spittler

 

Reshoring…

Remember th...


Conn's Picked as Small Cap Momentum and Value Play by Jefferies

Equities Staff | Equities.com |

Conn's is the smallest of the 17 companies on Jefferies' list.


North American Construction Group Beats Earnings Estimates, Nears Pre-Pandemic Trajectory

Edward Kim | Equities.com |

The construction and mining contractor provider finished a strong second half of 2021.


Keep Your Friends Close, But Your Enemies Closer — Part III

Michael McTague | Equities.com |

We conclude our examination of payback with a look at the economic success of small European countries like Ireland, led by Taoiseach Micheál Martin.


Samsung Vice Chair Lee in US To Finalize $17 Billion Chip Plant Site, Meet With Moderna on Vaccines

Kimberly Redmond | Equities.com |

Samsung Electronics Co vice president Jay Y. Lee has embarked on a high-profile business trip to the US to finalize the company’s plant to build a $17 billion semiconductor plant and discuss COVID-19 vaccines with Moderna Inc. 

Reuters reported that Samsung’s decision on where it will locate its new plant with coincide with Lee’s trip, which kicked off Sunday. https://www.reuters.com/business/samsungs-lee-visits-us-ahead-likely-17-bln-chip-plant-decision...


Moderna Cuts COVID-19 Vaccine Sales Forecast; Shares Plunge 16%

Reuters | Equities.com |

Moderna Inc (MRNA) on Thursday slashed the 2021 sales forecast for its COVID-19 vaccine by as much as $5 billion, as it struggles to fill vials and distribute them around the world, sending its shares down nearly 15% before the opening bell.

Moderna executives said production challenges now lie with bottling up doses, also known as fill and finish, and ramping up infrastructure to deliver them internationally, rather than production of raw material.


New Factory Orders Increase 1.2% in August, Greater Than Expected

Reuters | Equities.com |

New orders for U.S.-made goods accelerated in August, pointing to sustained strength in manufacturing even as economic growth appeared to have slowed in the third quarter because of shortages of raw materials and labor.

The Commerce Department said on Monday that factory orders increased 1.2% in August. Data for July was revised higher to show orders rising 0.7% in July instead of gaining 0.4% as previously reported. Economists polled by Reuters had forecast factory orders gaining 1.0%.


China's Purchasing Managers' Index Falls to 50.1 in August

AP News | Equities.com |

China’s factory activity decelerated in August as export demand weakened, a survey showed Tuesday.

The monthly purchasing managers’ index of the Chinese statistics bureau and an official industry group declined to 50.1 from July’s 50.4 on a 100-point scale on which numbers above 50 show activity increasing.


US Factory Orders Rose 1.5% in June, Ahead of Forecasts

Reuters | Equities.com |

New orders for U.S.-made goods increased more than expected in June, while business spending on equipment was solid, pointing to sustained strength in manufacturing even as spending is shifting away from goods to services.

The Commerce Department said on Tuesday that factory orders rose 1.5% in June after advancing 2.3% in May. Economists polled by Reuters had forecast factory orders increasing 1.0%.

Orders soared 18.4% on a year-on-...


Sponsored Financial Content

Market Movers